Characterization of patients receiving palliative chemo- and radiotherapy during end of life at a regional cancer center in Norway

Acta Oncologica

Volumn 54, Issue 3, 2015, Pages 395-402

  Anshushaug, Malin ^a,b   Gynnild, Mari Aas ^a,b   Kaasa, Stein ^a,b   Kvikstad, Anne ^a,b   Grønberg, Bjørn H ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; SERUM ALBUMIN;

AGE; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; METASTASIS; NEOPLASM; NORWAY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; STOMACH CANCER; TERMINAL CARE; URINARY TRACT CANCER; ADOLESCENT; ADULT; AGED, 80 AND OVER; BLOOD; CANCER CARE FACILITIES; CHILD; EPIDEMIOLOGY; HUMANS; MIDDLE AGED; MORTALITY; NEOPLASMS; PALLIATIVE CARE; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CANCER CARE FACILITIES; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NORWAY; PALLIATIVE CARE; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX;

EID: 84924276013     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.948061     Document Type: Article

References (25)

1. Andreis F, Rizzi A, Rota L, Meriggi F, Mazzocchi M, Zaniboni A. Chemotherapy use at the end of life. A retrospective single centre experience analysis. Tumori 2011;97:30-4.
2. Goncalves JF, Goyanes C. Use of chemotherapy at the end of life in a Portuguese oncology center. Support Care Cancer 2008;16:321-7.
3. Murillo JR, Jr., Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 2006;11:1095-9.
4. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. New Engl J Med 2010;363:733-42.
5. Tang ST, Liu TW, Shyu YI, Huang EW, Koong SL, Hsiao SC. Impact of age on end-of-life care for adult Taiwanese cancer decedents, 2001-2006. Palliat Med 2012;26:80-8.
6. Yun YH, Kwak M, Park SM, Kim S, Choi JS, Lim HY, et al. Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 2007;72:164-71.
7. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004;22:315-21.
8. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol 2008;26:3860-6.
9. Ho TH, Barbera L, Saskin R, Lu H, Neville BA, Earle CC. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 2011;29:1587-91.
10. Gonsalves WI, Tashi T, Krishnamurthy J, Davies T, Ortman S, Thota R, et al. Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran's Affairs cancer population. J Palliat Med 2011;14:1231-5.
11. Guadagnolo BA, Liao KP, Elting L, Giordano S, Buchholz TA, Shih YC. Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol 2013;31:80-7.
12. Kapadia NS, Mamet R, Zornosa C, Niland JC, D'Amico TA, Hayman JA. Radiation therapy at the end of life in patients with incurable nonsmall cell lung cancer. Cancer 2012;118:4339-45.
13. Gripp S, Mjartan S, Boelke E, Willers R. Palliative radiotherapy tailored to life expectancy in end-stage cancer patients: Reality or myth? Cancer 2010;116:3251-6.
14. Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: Prospective cohort study. Br Med J 2000;320:469-72.
15. Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. Br Med J 2003;327:195-8.
16. Glare P, Sinclair C, Downing M, Stone P, Maltoni M, Vigano A. Predicting survival in patients with advanced disease. Eur J Cancer 2008;44:1146-56.
17. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev 2013;39:534-40.
18. Smith TJ, Hillner BE. Bending the cost curve in cancer care. New Engl J Med 2011;364:2060-5.
19. Quill TE. Perspectives on care at the close of life. Initiating end-of-life discussions with seriously ill patients: Addressing the 'elephant in the room'. JAMA 2000;284: 2502-7.
20. Liu TW, Chang WC, Wang HM, Chen JS, Koong SL, Hsiao SC, et al. Use of chemotherapy at the end of life among Taiwanese cancer decedents, 2001-2006. Acta Oncol 2012;51:505-11.
21. Asola R, Huhtala H, Holli K . Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer. Breast Cancer Res Treat 2006;100: 77-82.
22. Colla CH, Morden NE, Skinner JS, Hoverman JR, Meara E. Impact of payment reform on chemotherapy at the end of life. Am J Managed Care 2012;18: e200-8.
23. Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: A global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999;52:101-9.
24. Saito AM, Landrum MB, Neville BA, Ayanian JZ, Earle CC. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care 2011;10:14.
25. Magarotto R, Lunardi G, Coati F, Cassandrini P, Picece V, Ferrighi S, et al. Reduced use of chemotherapy at the end of life in an integrated-care model of oncology and palliative care. Tumori 2011;97:573-7.